The Rheumatologist, Cancer and the Breakthrough, Part 2

In this episode, Leonard H. Calabrese, DO, is joined by his colleague and daughter Cassandra Calabrese, DO, as they discuss specifics of irAEs, including unusual toxicities, rheumatic conditions associated with checkpoint inhibitors and the rheumatologist's role in this new area of medicine.

Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.

• Intro :22
• Recap of Part 1 :40
• An interview with Cassandra Calabrese, DO 2:02
  • The number of patients with irAEs will grow 2:22
  • How many people actually experience irAEs? 3:40
  • Any examples of unusual toxicities? 5:49
  • What's the timeline? 6:51
  • Have you seen patients with delayed onset? 8:10
  • Most of our patients have had one irAE or another beforehand 9:04
  • Who's the captain of this ship? 10:15
  • What about inflammatory arthritis? 10:55
  • What about polymyalgia rheumatica? 13:48

Brought to you by GSK. Consider the long-term impact of disease activity, flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com

• What about sicca, is it Sjogren's? 16:22
• Can you tell us about myositis in this context? 18:38
• An overview of the guidelines 21:47
• Check out our article in March Current Opinions in Rheumatology 24:12
• What about patients with preexisting autoimmunity? 24:33
• Are you worried about blunting tumor response? 27:10
• Are there any biomarkers to predict this? 28:30
• How have you been working with oncologists to manage/educate? 29:42
• What about meetings? 31:04
• Rheumatologists have a special place in this new area of medicine 31:45

We'd love to hear from you! Send your comments/questions to [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum @LCalabreseDO @CCalabreseDO

Disclosure: Brown and Cassandra Calabrese report no relevant financial disclosures. Leonard Calabrese reports serving as an investigator and a consultant to Horizon Pharmaceuticals.

Cassandra Calabrese, DO, is associate staff member in the department of rheumatic and immunologic disease and department of infectious disease at the Cleveland Clinic. Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology and director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic.